$ALTO

Alto Ingredients, Inc.

No enriched coverage for $ALTO in the last 7 days.

$39K
—
NATHAN GILBERT E
0%
See all $ALTO insider activity →
Med

Here are Wednesday's biggest analyst calls: Nvidia, SpaceX, Apple, Tesla, Target, Amazon, Microsoft & more

Analysts made several calls: UBS kept Apple neutral citing stable iPhone wait times. Wells Fargo upgraded Pinnacle Financial and downgraded Ally Financial. Deutsche Bank initiated FormFactor as buy. William Blair initiated CoreWeave and Nebius Group as outperform. Bank of America reiterated Nvidia, Intel, Marvell, Micron, and Lam Research as buy. Citi initiated Nuvation Bio as buy and downgraded Moderna to sell. HSBC upgraded Target to buy. Morgan Stanley reiterated Tesla as equal weight.

Can Alto Ingredients Sustain Gains as Alcohol Premiums Narrow?

Alto Ingredients (ALTO) reported higher high-quality alcohol volumes (+3.6M gallons YoY) in Q2 2026, but narrower premiums over ethanol reduced revenues by $2.9M. Hedging strategies offset some impact, limiting net premium decline to 2 cents/gallon. Profitability increased modestly despite softer premiums. Shares fell 5.6% in the past month, underperforming peers. Forward P/S ratio is 0.34, below industry average 3.33. Earnings estimates declined 27.8% and 66.3% for 2026 and 2027, respectively.

ALTO sentiment & insider activity

Recent ALTO coverage spans earnings, financial news and insider activity.

In the last 30 days, ALTO insiders filed 1 SEC Form 4 transaction — 1 purchase ($39K) and no sales. The most active reporter was NATHAN GILBERT E with 1 filing.

What's driving ALTO

AlphAI scores every news story that mentions ALTO with an AI model for sentiment and relevance, and aggregates insider trades from Alto Ingredients, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ALTO

Score
$AAPLMed

Here are Wednesday's biggest analyst calls: Nvidia, SpaceX, Apple, Tesla, Target, Amazon, Microsoft & more

Analysts made several calls: UBS kept Apple neutral citing stable iPhone wait times. Wells Fargo upgraded Pinnacle Financial and downgraded Ally Financial. Deutsche Bank initiated FormFactor as buy. William Blair initiated CoreWeave and Nebius Group as outperform. Bank of America reiterated Nvidia, Intel, Marvell, Micron, and Lam Research as buy. Citi initiated Nuvation Bio as buy and downgraded Moderna to sell. HSBC upgraded Target to buy. Morgan Stanley reiterated Tesla as equal weight.

Can Alto Ingredients Sustain Gains as Alcohol Premiums Narrow?

Alto Ingredients (ALTO) reported higher high-quality alcohol volumes (+3.6M gallons YoY) in Q2 2026, but narrower premiums over ethanol reduced revenues by $2.9M. Hedging strategies offset some impact, limiting net premium decline to 2 cents/gallon. Profitability increased modestly despite softer premiums. Shares fell 5.6% in the past month, underperforming peers. Forward P/S ratio is 0.34, below industry average 3.33. Earnings estimates declined 27.8% and 66.3% for 2026 and 2027, respectively.

$ALTOMedAI 9/10

Alto (ALTO) Q2 2026 Earnings Call Transcript

Alto Ingredients (ALTO) reported Q2 2026 results in an earnings call. Net sales rose to $245.7M, adjusted EBITDA was $23.7M, and net income attributable to common stockholders was $11.4M ($0.15/diluted share). Full-year Section 45Z guidance is $15M to $16M. Management discussed capacity expansion, CO2 storage, and a $50M at-the-market equity program.

Alto Ingredients, Inc. (ALTO): Entry into a Material Definitive Agreement

Alto Ingredients, Inc. (ALTO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On August 5, 2026, Alto Ingredients, Inc. (the “Company”) entered into an At-The-Market Issuance Sales Agreement (the “Sales Agreement”) with Craig-Hallum Capital Group LLC (the “Designated Agent”), The Benchmark Company, LLC

Alto Ingredients, Inc. Reports Second Quarter 2026 Results

Alto Ingredients, Inc. (ALTO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Alto Ingredients, Inc. Reports Second Quarter 2026 Results Q2 2026 Gross Profit of $16.6 Million Increased $18.6 Million Q2 2026 Net Income of $11.4 Million, or $0.15 per Share, Improved $22.7 Million Q2 2026 Adjusted EBITDA of $23.7 Million Improved $23.9 Million Pe

The $10K Portfolio: Gunnin’ for Some More Smith & Wesson

The FBI reported July firearm background checks rose 9.3% to 2,194,563 versus July 2025, the second straight monthly increase. The article links checks to firearm demand and notes exposure for Smith & Wesson (SWBI) and Sturm Ruger (RGR). It also lists analyst rating/price-target updates for OCUL, RKLB, VELO, and ONDS, plus upcoming earnings expectations for several stocks.

Alto Ingredients partners on $16M Illinois River project to boost product flow

Alto Ingredients, according to the company, is partnering with the Heart of Illinois Port District and the City of Pekin on a $16M Illinois River project to improve product flow from its Pekin campus to barges for export. Funding includes an $11M federal grant request, $1M state request, and about $4M from Alto. Federal grant results expected by year end, with completion around 2029.

$ALTOLow

Alto Ingredients, Inc. (ALTO): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Alto Ingredients, Inc. (ALTO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ea029568801ex10-1.htm ALTO INGREDIENTS, INC. 2026 OMNIBUS INCENTIVE PLAN Exhibit 10.1 ALTO INGREDIENTS, INC. 2026 OMNIBUS INCENTIVE PLAN ALTO INGREDIENTS, INC., a Delaware corporation, sets forth herein the terms of its 2026 Omnibus Incentive Plan, as follows: 1. PURPOS

Related tickers